Self-replicating RNA Liposome for Localized IL-12 Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current IL-12 therapies for cancer treatment face challenges due to toxicity, marginal efficacy, and a strong immunosuppressive environment in humans, leading to the need for an improved therapeutic approach that minimizes interferon-gamma toxicity and enhances antitumor immune responses.
Innovation Solution
A self-replicating RNA (srRNA) encoding IL-12, packaged in biodegradable ionizable cationic liposomes, which triggers strong immune and T-cell responses by self-amplification within transduced cells, providing sustained IL-12 expression and localized high concentrations, thereby stimulating antitumor effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If repeated administration of IL-12 is performed, then anti-cancer activity is maintained, but interferon-gamma toxicity increases and efficacy declines
Solution Approach 1:
The patent employs self-replicating RNA that autonomously amplifies within host cells to sustain IL-12 production without requiring repeated external administration. The RNA replicon self-propagates through cellular replication, creating a self-sustaining system that maintains therapeutic effect while eliminating the need for continuous dosing that causes toxicity accumulation.
Solution Approach 2:
The self-replicating RNA establishes continuous IL-12 production within transduced cells, maintaining therapeutic activity over time without interruption. This continuous action eliminates the need for repeated administrations that lead to accumulating interferon-gamma toxicity, as the system sustains itself through cellular division and RNA replication.
2Reliability
If conventional IL-12 therapy is administered, then immune response is activated, but toxicity and marginal efficacy occur in clinical settings
Solution Approach 1:
The patent delivers RNA replicon locally to tumor sites through intratumoral injection, concentrating the therapeutic effect at the tumor location rather than systemically. This localized approach activates immune response specifically at the tumor site, reducing off-target toxicity while maintaining effective local immune activation and IL-12 concentrations.
Solution Approach 2:
The self-replicating RNA system autonomously produces IL-12 within transduced tumor cells without requiring continuous external administration. This self-sustaining mechanism maintains reliable immune response activation at the tumor site while eliminating the toxicity associated with repeated systemic dosing of conventional IL-12 therapy.
3Reliability
If high concentrations of IL-12 are achieved through repeated administration, then antitumor effect is enhanced, but interferon-gamma mediated toxicity increases
Solution Approach 1:
The self-replicating RNA maintains continuous IL-12 production within transduced cells, providing sustained antitumor effect without the need for repeated administrations. This continuous local production achieves high concentrations of IL-12 at the tumor site while avoiding the accumulating interferon-gamma toxicity that results from repeated systemic administrations.
Solution Approach 2:
The patent concentrates IL-12 production locally at the tumor site through intratumoral delivery of RNA replicon, achieving high local concentrations that enhance antitumor effect. This localized concentration strategy maintains effective antitumor activity while minimizing systemic interferon-gamma toxicity compared to repeated systemic administrations.
Data Source
AI summary
The disclosure relates to a liposome packaged RNA replicon encoding IL-12. Included are methods for preparing and administering the liposome packaged RNA replicon encoding IL-12.